Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Japan-India EPA Not Intended to Preferentially Treat Applications from Indian Companies: Korosho
November 8, 2010
- MINCLEA Approved for Pretreatment for Endoscopy: Nihon Pharma
November 8, 2010
- TAK-442 Fails to Show Efficacy in Multinational PII Trial: Takeda
November 8, 2010
- FDA Approves DSP's Schizophrenia Drug Lurasidone
November 8, 2010
- Lyrica Approved for Pain Due to Peripheral Neuropathy: Pfizer Japan
November 8, 2010
- Hizentra Shows Efficacy, Safety in PIII in Europe
November 8, 2010
- Eisai's Botulinum Toxin B, DSP's Repaglinide Recommended for Approval
November 8, 2010
- Benesis Obtains Additional Indication for Venoglobulin: MTPC
November 8, 2010
- Kobayashi Medical Falsifies Application Data for 2 Implant Products
November 8, 2010
- Only APIs Used for 1 Year or More on the Market to Be Approved for Use in Combination Drugs
November 8, 2010
- Botox Approved for Lower/Upper Limb Spasticity: GSK
November 8, 2010
- Erbitux Achieves OS of 28.3 Months in Wild-Type KRAS Tumor Patients
November 8, 2010
- Astellas to Transfer Intal to sanofi-aventis
November 1, 2010
- Dabigatran Approved for SPAF in the US
November 1, 2010
- Cabazitaxel Improves Survival in Prostate Cancer Patients
November 1, 2010
- Astellas Licenses Dysuria Drug from ASKA
November 1, 2010
- MSD Launches Higher-Strength Asmanex
November 1, 2010
- BI's Combination Drug for Hypertension Receives EU Approval
November 1, 2010
- Afinitor plus Sandostatin Extended PFS in NET Patients: Novartis
November 1, 2010
- Shionogi Allies with Swedish Academia
November 1, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…